Petros Pharmaceuticals
PTPI
PTPI was delisted on the 21st of May, 2025.
17 hedge funds and large institutions have $4.23M invested in Petros Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 5 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
9% more capital invested
Capital invested by funds: $3.9M → $4.23M (+$335K)
0.01% more ownership
Funds ownership: 0.04% → 0.05% (+0.01%)
15% less funds holding
Funds holding: 20 → 17 (-3)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $37K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Shay Capital
New York
|
+$794K |
| 2 |
Renaissance Technologies
New York
|
+$159K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$134K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$101K |
| 5 |
FIA
FNY Investment Advisers
New York
|
+$75.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NP
NorthRock Partners
Minneapolis,
Minnesota
|
-$179K |
| 2 |
CC
Cannell & Co
New York
|
-$112K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$13K |
| 4 |
APA
American Portfolios Advisors
Holbrook,
New York
|
-$4.4K |
| 5 |
IA
IFP Advisors
Tampa,
Florida
|
-$2.83K |
PTPI Hedge Fund Activity: Q1 2021 in Review
17 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Petros Pharmaceuticals (PTPI) for Q1 2021, worth a combined $4.23M — up 8.6% from $3.9M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of PTPI and 4 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 4 added.
The largest buyer was Shay Capital, adding an estimated $794K. The largest seller was NorthRock Partners, cutting an estimated $179K.
- 17 institutional investors held Petros Pharmaceuticals (PTPI) as of Q1 2021, down from 20 in Q4 2020.
- Funds reported $4.23M of Petros Pharmaceuticals stock for Q1 2021, up 8.6% quarter-over-quarter.
- 4 funds opened new Petros Pharmaceuticals positions in Q1 2021 and 5 closed out, a net change of -1 holder.
- The largest Petros Pharmaceuticals buyer in Q1 2021 was Shay Capital, an estimated $794K added.
- The largest Petros Pharmaceuticals seller in Q1 2021 was NorthRock Partners, an estimated $179K sold.
Based on aggregated 13F filings for Q1 2021.